Rasna Therapeutics, Inc. Appoints Dr Alessandro Padova as Chairman

NEW YORK–(BUSINESS WIRE)– Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage
biotechnology company focused on the development of cancer drugs, today
announced the appointment of Dr Alessandro Padova as Chairman with
immediate effect.

“We are delighted to welcome Alessandro to the Rasna team and look
forward to the positive contribution of his leadership, experience and
successful international track record of progressing assets through
clinical development,” commented Jim Tripp, CEO of Rasna.

Dr Padova will continue to serve in his role as Chief Executive Officer
of Ri.MED Foundation, a unique US-Italy public-private translational
research enterprise. He has previously held senior executive, managerial
and scientific roles in the pharmaceutical and biotechnology sector with
several prestigious UK and Italian biotech companies including Peptide
Therapeutics, Medivir UK, Astex Technology, C4T S.C.ar.l., Siena Biotech
and IRBM Science Park, where he led and implemented business, management
and R&D strategies.

Dr Padova obtained a BSc in Chemistry from the University of Kent and a
PhD in Synthetic Organic Chemistry in 1994 at Exeter University,
followed by an industrial post-doctoral fellowship at Parke-Davis
Neuroscience Research Centre in Cambridge, UK.

###

About Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company
focused primarily on the development of drug candidates for leukemia and
lymphoma. Abnormal epigenetic modification is recognized to play an
important role in the pathogenesis of acute myeloid leukemia (AML),
leading to silencing of genes involved in tumor suppression and cellular
reproduction. Rasna’s focus on inhibition of lysine specific
demethylase-1 (LSD1), an enzyme involved in epigenetic control,
represents a promising and novel approach towards AML. Rasna has
developed novel irreversible and reversible LSD1 regulators that have
shown appropriate effects on the LSD1 gene in-vitro and in
IND-enabling pre-clinical studies.

Rasna Therapeutics Forward-Looking Statements

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect Rasna Therapeutics’
business and Rasna Therapeutics undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161018006191/en/